Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Identifying Novel Therapeutic Targets by Combining Transcriptional Data with Ordinal Clinical Measurements

ABSTRACT: Identifying Novel Therapeutic Targets by Combining Transcriptional Data with Ordinal Clinical Measurements

PROVIDER: PRJNA386152 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Similar Datasets

RNA-seq dataset for Identifying Novel Therapeutic Targets by Combining Transcriptional Data with Ordinal Clinical Measurements

Project description:The widespread adoption of transcriptional profiling has led to immense repositories of data that may contain critical insights for developing new therapies. Current approaches to mining these data largely rely on binary classifications of disease versus control. These methods are not able to incorporate measures of disease severity, which are often available. We report an analytical approach to integrate ordinal clinical information with transcriptomics. We have applied this method to public data for a large cohort of Huntington’s disease patients and controls, identifying and prioritizing phenotype-associated genes. To validate the approach, we have performed viability, siRNA knockdown, mRNA-seq, and ChIP-seq on striatal precursor cells expressing either full-length wild type (STHdh Q7) or mutant huntingtin (STHdh Q111). We have verified the role of a high-ranked gene in dysregulation of sphingolipid metabolism in the disease and demonstrated that inhibiting the enzyme, SPL, has neuroprotective effects in HD models. We have shown that one consequence of inhibiting SPL is the intracellular inhibition of HDACs, thus linking our observations in sphingolipid metabolism to a well-characterized HD pathway. Our approach is easily applied to any data with ordinal clinical measurements, and may deepen our understanding of disease processes.

2017-05-11 | GSE98739 | GEO

ChIP-seq dataset for H3K9ac in Identifying Novel Therapeutic Targets by Combining Transcriptional Data with Ordinal Clinical Measurements

2017-05-11 | GSE98738 | GEO

Identifying Novel Therapeutic Targets by Combining Transcriptional Data with Ordinal Clinical Measurements

Project description:This SuperSeries is composed of the SubSeries listed below.

2017-05-11 | GSE98740 | GEO

Identifying therapeutic targets by combining transcriptional data with ordinal clinical measurements.

Project description: Not available

| S-EPMC5606996 | biostudies-literature

Generating automated kidney transplant biopsy reports combining molecular measurements with ensembles of machine learning classifiers

Project description:Generating automated kidney transplant biopsy reports combining molecular measurements with ensembles of machine learning classifiers

| PRJNA511014 | ENA

Mus musculus

Project description:RNA-seq dataset for Identifying Novel Therapeutic Targets by Combining Transcriptional Data with Ordinal Clinical Measurements

| PRJNA386216 | ENA

Identifying CNS-colonizing T cells as potential therapeutic targets to prevent progression of multiple sclerosis

Project description:Identifying CNS-colonizing T cells as potential therapeutic targets to prevent progression of multiple sclerosis

| PRJNA604770 | ENA

Mus musculus

Project description:ChIP-seq dataset for H3K9ac in Identifying Novel Therapeutic Targets by Combining Transcriptional Data with Ordinal Clinical Measurements

| PRJNA386217 | ENA

IDENTIFYING KEY DRIVER GENES OF INNATE IMMUNE PATHWAYS AS NOVEL THERAPEUTIC TARGETS IN RENAL ALLOGRAFT REJECTION

Project description:IDENTIFYING KEY DRIVER GENES OF INNATE IMMUNE PATHWAYS AS NOVEL THERAPEUTIC TARGETS IN RENAL ALLOGRAFT REJECTION

| PRJNA574297 | ENA

Combining LSD1 and JAK-STAT inhibition targets Down syndrome-associated myeloid leukemia at its core

Project description:We investigated the combination of the irreversible LSD1 inhibitor T-3775440 and the JAK1/JAK2 inhibitor ruxolitinib as novel therapeutic approach in ML-DS which is specifically designed to target key hallmarks of ML-DS leukemogenesis. We observed synergistic anti-leukemic effects by combining both drugs. To elucidate the underlying molecular mechanisms we performed RNAseq in two independent patients samples treated with vehicle, LSD1 inhibitor or ruxolitinib monotherapy or the combination of both drugs.

2022-05-27 | GSE201093 | GEO

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data